吉西他滨联合化疗方案治疗复发转移性乳腺癌的临床疗效观察

目的:观察吉西他滨与顺铂联合以及吉西他滨与紫杉醇联合治疗复发转移性乳腺癌的疗效和不良反应。方法:本研究收集65例女性乳腺癌术后复发转移的患者作为研究对象。随机分成两组,分别应用吉西他滨与顺铂(GP方案组)、吉西他滨与紫杉醇(GT方案组)联合进行治疗。GP方案组患者有30例,第1天、第8天用吉西他滨800mg~1000mg/m2溶于0.9%的100mL生理盐水中静脉滴注;第1天~第3天,21天重复用顺铂30mg/m2溶于0.9%的250mL生理盐水中静脉滴注;GT方案组患者有35例,吉西他滨的使用方法与GP方案组相同,第2天,21重复用紫杉醇135mg/m2溶于0.9%的500mL生理盐水中静脉滴注。对化疗时产生的不良反应进行对症处理。结果 :GP方案组化疗有效率为46.67%,疾病控制率为70.00%;GT方案组化疗有效率为42.86%,疾病控制率为68.57%,两组比较差异均无统计学意义(P0.05)。GT组脱发的发生率为62.86%,明显高于GP组的10.00%(P0.001),其他不良反应在两组之间差异无统计学意义(P0.05)。结论:GP方案和GT方案在治疗复发转移性乳腺癌有较好的疗效,不良反应较轻,可作为复方转移性乳腺的一种化疗方案。

Clinical Observation of Chemotherapy Regimen Based on Gemcitabine in the Treatment of Metastasis Breast Cancer

Objective： To compare the efficacy and side effects of GP and GT regimen in the treatment of metastasis breast cancer. Methods： We collected 65 cases of female patients with metastasis breast cancer as research subjects, which were randomly divided into two groups and jointly treated with GP regimen or GT regimen.There were 30 cases of patients in GP regimen group which were injected with Gemcitabine 800mg - 1000mg/m2 dissolved in 0.9% saline infusion 100ml in day 1 and day 8, with Cisplatin 30mg/m2 dissolved in 0.9% saline infusion 250 mL in other days; There were 35 cases of patients in GT regimen group which were injected with Gemcitabine 800rag - 1000mg/m2 dissolved in 0.9% saline infusion 100ml in day 1 and day 8, with taxol 135mg/m2 dissolved in 0.9% saline infusion 500ml in other days. Take expectant treatment when patients have side effects. Results： The efficiency of chemotherapy in GP regimen group was 46.67% and 42.86% in GT regimen group,the disease control rate in GP regimen group was 70.00% and 68.57% in GT regim- en group, the difference was all not statistically significant（P〉0.05）. The incidence of alopecia in GT regimen group was 62.86%, signifi- cantly higher than 10.00% in GP regimen group （P〈0.001）, Other side effects between the two groups showed no significant difference （P〉0.05）. Conclusion： GP and GT regimen are both effective in the treatment of metastasis breast cancer, and also, they both have mild side effects.